Bolthouse Investments LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

by · The Markets Daily

Bolthouse Investments LLC bought a new stake in Pfizer Inc. (NYSE:PFE – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,274 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.

A number of other hedge funds have also made changes to their positions in the stock. Nordea Investment Management AB lifted its position in Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after buying an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI grew its holdings in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after acquiring an additional 159,984 shares in the last quarter. Copley Financial Group Inc. acquired a new position in shares of Pfizer in the third quarter worth $577,000. Mcdonald Partners LLC raised its holdings in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after acquiring an additional 9,963 shares in the last quarter. Finally, Merit Financial Group LLC boosted its position in Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock valued at $3,395,000 after purchasing an additional 48,397 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.7 %

PFE stock opened at $22.95 on Friday. The stock has a market capitalization of $130.16 billion, a price-to-earnings ratio of 16.28, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a 50-day moving average of $24.58 and a two-hundred day moving average of $25.97. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.49%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday. They issued a “neutral” rating and a $24.00 price objective on the stock. UBS Group cut their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 8th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.57.

Get Our Latest Report on Pfizer

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).